Results 131 to 140 of about 1,045,316 (267)

Vaginal cancer in the second trimester of pregnancy: Successful conservative surgery and 21-year disease-free survival. [PDF]

Gynecol Oncol Rep
Tjalma W, Caris Alias Reynders F, Eelen C, Konje J, Deckers F, Joye I, Papadimitriou K, Subbian A.   +7 more
europepmc   +1 more source

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Preoperative nutritional status and sarcopenia are associated with disease-free survival in patients with resected pancreatic neuroendocrine tumors. [PDF]

Front Oncol
Li J, Lai M.
europepmc   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

IMPROVED DISEASE FREE SURVIVAL IN JMML. THE DUTCH EXPERIENCE.

EJC Paediatric Oncology
Dorine Bresters, Valérie de Haas, Martine Mol, Katja Heitink, Arjenne Kors, Mirjam Belderbos, Marco Koudijs, Esmé Waanders, Kirsten Thus, Marc Bierings   +9 more
doaj   +1 more source

Primary keratinizing squamous cell carcinoma of the renal pelvis with pancreatic tail invasion and five-year disease-free survival: A case report. [PDF]

Urol Case Rep
Nuraly S, Bolatov D, Shakeyev K, Zhumakayev A, Kukushkina E.   +4 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Prolonged disease-free survival with immunotherapy combined with chemotherapy in a patient with advanced stage large cell neuroendocrine carcinoma of the uterus. [PDF]

Gynecol Oncol Rep
Yoh K, Smithgall MC, Tessler G, Kulkarni A, Lenis AT, Ghiassi Z, Wright JD, Dioun S.   +7 more
europepmc   +1 more source

Can Disease-Free Survival Be a Surrogate for Overall Survival for Drug Approvals? [PDF]

JNCI Journal of the National Cancer Institute, 2004
openaire   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source